Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma

A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. ASCO Gastrointestinal Cancers Symposium. 2004.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.